Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: EagleC who wrote (8497)	3/11/1998 2:18:00 PM
From: Hope	Respond to of 14328

Triby is being looked at over at The 56 Point TA, Charts With Attitude thread: Saturday, Mar 7 1998 9:21AM EST You have quite a bit of overhead on TRIBY...Potential initial run once this is cleared out with expanding volume is 2.67-2.75...Trading range presently from 2.03-1.84...Relative Strength moved above 50 on Friday, which means, keep this one on radar.. exchange2000.com

To: EagleC who wrote (8497)	3/11/1998 3:04:00 PM
From: Scott H. Davis	Respond to of 14328

30% revenue growth can yield great EPS and share price growth IF if is significantly greater than the % increase in expenses and outstanding shares. Case in point. bigcharts.com for a better example, go over to indicators, and select rolling EPS for the lower indicator. wsrn.com note, WSRN has some bad data, so ignore the industry comparison at the bottom, its drunk. I think EQNX revenue for qtr3 96 was in the 6.4 to 6.6 range, so the revenue growth for 15 months is good but not great. But note - EPS is going up much faster than sales due to expanding margins. Expenses are under control, and they've had a modest share buyback program. I'll take 30% revenue growth any day. The big question is the expenses & shares outstanding. OK sermon over, I'm probably becoming very booring, but I trust I've made my point. Scott